Q&A: Page 2

Exclusive interviews with industry leaders

  • A nurse in green scrubs puts a smart watch on a patient in a grey, blue and orange striped shirt.
    Image attribution tooltip
    Giuseppe Lombardo via Getty Images

    Personalized data could bring PhysIQ to the forefront of clinical trial evolution

    The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

    Karissa Waddick • July 28, 2022
  • long covid
    Image attribution tooltip
    Lisa Maree Williams via Getty Images

    Lupus discovery lends clues to the fight against long COVID

    So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.

    Kelly Bilodeau • July 27, 2022
  • A man walks out of the Pfizer world headquarters building.
    Image attribution tooltip
    Chris Hondros / Staff via Getty Images

    Behind Pfizer's new quest to target a 'transformation' in pharma

    A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

    Kelly Bilodeau • July 25, 2022
  • gene therapy
    Image attribution tooltip
    Stock via Getty Images

    First 90 Days: Anjarium Biosciences' Stephen Yoo

    The incoming CEO aims to build on the buzz around the company’s leading-edge gene therapy tech.

    Kim Ribbink • July 15, 2022
  • A black stethoscope rests diagonally on a rainbow flag background.
    Image attribution tooltip
    Sasirin Pamai via Getty Images

    Janssen extends LGBTQ mental health outreach beyond Pride Month

    The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.

    Karissa Waddick • July 14, 2022
  • Two packets of pills and a vaccine vials sit atop a blue surgical mask.
    Image attribution tooltip
    Anna Kim via Getty Images

    COVID won't evolve to become 'less deadly' — and RedHill is prepping for the long haul

    RedHill Biopharma’s chief operating officer, Guy Goldberg, says the company’s oral COVID-19 therapy could still be needed on a global scale.

    Kim Ribbink • July 12, 2022
  • Image attribution tooltip
    Stock via Getty Images

    The CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing

    Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.

    Meagan Parrish • July 7, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

    As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

    Kim Ribbink • June 30, 2022
  • Katalin Kariko and Drew Weissman
    Image attribution tooltip
    Permission granted by University of Pennsylvania

    The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

    The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.

    Michael Gibney • June 29, 2022
  • Image attribution tooltip

    Permission granted by Dan Vahdat.

    'Nobel Prize of pharma' helps put Huma's digital health platform on the global map

    The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.

    Kim Ribbink • June 23, 2022
  • schizophrenia
    Image attribution tooltip
    Stock via Getty Images

    Biotech spotlight: Karuna Therapeutics' mission to rejuvenate the field of neuroscience

    An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

    Kim Ribbink • June 16, 2022
  • Scientist pipetting sample into a multi well plate
    Image attribution tooltip
    iStock via Getty Images

    Why biomanufacturing is the next innovation frontier for genomic therapies

    While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

    Meagan Parrish • June 13, 2022
  • Editas Medicine CEO Gilmore O'Neill
    Image attribution tooltip
    Permission granted by Editas/Gilmore O'Neill

    First 90 Days: Editas Medicine's Gilmore O'Neill

    The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

    Michael Gibney • June 13, 2022
  • brain drug
    Image attribution tooltip
    Stock via Getty Images

    A combo of precision meds and diagnostics could disrupt mental healthcare

    HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

    Kelly Bilodeau • June 8, 2022
  • David Jimenez
    Image attribution tooltip

    Permission granted by David Jimenez.

    First 90 Days: Janssen Immunology's David Jimenez

    The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

    Taren Grom • June 6, 2022
  • Sosei Heptares CEO Chris Cargill
    Image attribution tooltip
    Permission granted by Sosei Heptares/Chris Cargill

    First 90 Days: Sosei Heptares' Chris Cargill

    The company’s new CEO is looking to drive growth through collaboration and transparency.

    Kim Ribbink • May 31, 2022
  • CEO of Syneos Health
    Image attribution tooltip

    Permission granted by Michelle Keefe. 

    First 90 Days: Syneos Health's Michelle Keefe

    The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.

    Taren Grom • May 23, 2022
  • Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
    Image attribution tooltip
    Stock via Getty Images

    The UK-based company that's striving to overcome the limitations of T cell receptor innovation

    Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

    Kim Ribbink • May 23, 2022
  • Dozens of orange prescription bottles with white caps and labels layered in a jumple.
    Image attribution tooltip
    iStock via Getty Images

    Ironwood Pharmaceuticals is charting a course to become a giant in GI

    Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market. 

    Karissa Waddick • May 19, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    BriOri BioTech sets the stage for the comeback of Vioxx

    With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.

    Kelly Bilodeau • May 17, 2022
  • Doctor examines DNA molecules on blurred background.
    Image attribution tooltip
    Natali_Mis via Getty Images

    Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

    Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

    Michael Gibney • May 17, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

    With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

    Taren Grom • May 9, 2022
  • Image attribution tooltip
    Stock via Getty Images

    One company's failed drug is this company's 'jewel'

    Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

    Meagan Parrish • May 2, 2022
  • Headshot of Alan Millar.
    Image attribution tooltip

    Permission granted by Alan Millar. 

    How an open platform can shake up the drug development process

    TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

    Kim Ribbink • April 28, 2022
  • Vital sign monitor in tablet PC.
    Image attribution tooltip
    iStock via Getty Images

    Real-world data is making drug development more true to life

    How RWD is moving from the background to the spotlight in pharma’s development process.

    Kelly Bilodeau • April 26, 2022